2,779 Shares in Baxter International Inc (BAX) Purchased by Rice Partnership LLC

Rice Partnership LLC acquired a new stake in shares of Baxter International Inc (NYSE:BAX) in the first quarter, HoldingsChannel reports. The fund acquired 2,779 shares of the medical instruments supplier’s stock, valued at approximately $226,000.

Several other large investors have also made changes to their positions in BAX. Cetera Advisors LLC grew its position in Baxter International by 24.2% in the 1st quarter. Cetera Advisors LLC now owns 5,662 shares of the medical instruments supplier’s stock worth $459,000 after purchasing an additional 1,102 shares during the last quarter. Goelzer Investment Management Inc. grew its position in Baxter International by 36.2% in the 1st quarter. Goelzer Investment Management Inc. now owns 10,127 shares of the medical instruments supplier’s stock worth $823,000 after purchasing an additional 2,694 shares during the last quarter. Stephens Inc. AR grew its position in Baxter International by 10.9% in the 1st quarter. Stephens Inc. AR now owns 16,903 shares of the medical instruments supplier’s stock worth $1,374,000 after purchasing an additional 1,660 shares during the last quarter. Boston Common Asset Management LLC grew its position in Baxter International by 5.9% in the 1st quarter. Boston Common Asset Management LLC now owns 83,176 shares of the medical instruments supplier’s stock worth $6,763,000 after purchasing an additional 4,655 shares during the last quarter. Finally, BHK Investment Advisors LLC grew its position in Baxter International by 37.2% in the 1st quarter. BHK Investment Advisors LLC now owns 4,343 shares of the medical instruments supplier’s stock worth $353,000 after purchasing an additional 1,177 shares during the last quarter. 86.38% of the stock is owned by institutional investors and hedge funds.

In related news, SVP Scott Pleau sold 9,710 shares of the stock in a transaction that occurred on Friday, March 29th. The shares were sold at an average price of $80.00, for a total transaction of $776,800.00. Following the completion of the sale, the senior vice president now directly owns 29,786 shares of the company’s stock, valued at $2,382,880. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Giuseppe Accogli sold 38,297 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $76.78, for a total transaction of $2,940,443.66. Following the sale, the senior vice president now directly owns 70,001 shares of the company’s stock, valued at $5,374,676.78. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 57,187 shares of company stock valued at $4,447,619. Company insiders own 0.70% of the company’s stock.

Several research firms have commented on BAX. Wells Fargo & Co upped their target price on shares of Baxter International from $80.00 to $89.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 3rd. Zacks Investment Research cut shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, April 2nd. Barclays upped their target price on shares of Baxter International from $72.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Monday, April 15th. Cowen set a $75.00 target price on shares of Baxter International and gave the stock a “hold” rating in a research report on Monday, April 22nd. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $88.00 price target (up from $80.00) on shares of Baxter International in a research note on Monday. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $78.69.

Shares of NYSE:BAX opened at $75.94 on Monday. The company has a market capitalization of $38.77 billion, a PE ratio of 24.90, a P/E/G ratio of 1.79 and a beta of 0.96. Baxter International Inc has a twelve month low of $61.05 and a twelve month high of $82.25. The company has a quick ratio of 1.50, a current ratio of 1.83 and a debt-to-equity ratio of 0.50.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Thursday, April 25th. The medical instruments supplier reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.08. The company had revenue of $2.63 billion during the quarter, compared to analyst estimates of $2.61 billion. Baxter International had a net margin of 14.27% and a return on equity of 20.04%. The business’s revenue for the quarter was down 1.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.70 EPS. Equities analysts forecast that Baxter International Inc will post 3.32 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, July 1st. Stockholders of record on Friday, June 7th will be paid a $0.22 dividend. This is a positive change from Baxter International’s previous quarterly dividend of $0.19. This represents a $0.88 dividend on an annualized basis and a dividend yield of 1.16%. The ex-dividend date of this dividend is Thursday, June 6th. Baxter International’s dividend payout ratio is currently 24.92%.

ILLEGAL ACTIVITY WARNING: This article was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/13/2779-shares-in-baxter-international-inc-bax-purchased-by-rice-partnership-llc.html.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

See Also: What is the Quick Ratio?

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.